-+ 0.00%
-+ 0.00%
-+ 0.00%

TG Therapeutics Affirms FY2026 Sales Guidance of $875.000M-$900.000M

Benzinga·02/26/2026 12:03:19
Listen to the news

026 Financial Guidance

  • Full year 2026 target total global revenue of approximately $875-$900 million, including BRIUMVI U.S. net product revenue of approximately $825-$850 million
  • Q1 2026 target BRIUMVI U.S. net product revenue of approximately $185-$190 million 

     
  • Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, in addition to approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs